Halozyme Therapeutics | HALO - Selling And Administration Expenses


Halozyme Therapeutics reported $64.64M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amarin USD 17.94M 17.86M Sep/2025
Amgen USD 1.94B 237M Dec/2025
Baxter International USD 761M 53M Dec/2025
Cara Therapeutics USD 4.64M 2.19M Mar/2025
Cytokinetics USD 158.75M 93.03M Sep/2025
DBV Technologies USD 3.63M 3.18M Sep/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Intrexon USD 10.31M 41K Jun/2024
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
MannKind USD 29.09M 2.53M Sep/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Pfizer USD 4.08B 894M Dec/2025
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
United Therapeutics USD 152M 60.5M Sep/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024